Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto
申请人:Emory University
公开号:US10759803B2
公开(公告)日:2020-09-01
This disclosure relates to asparagine endopeptidase inhibitors for managing cancer and compositions related thereto. In certain embodiments, the asparagine endopeptidase inhibitors are substituted 3,7-dihydropurine-2,6-dione derivatives useful for treating or preventing metastasis, tumor growth, and/or cancer. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising an asparagine endopeptidase inhibitor and a pharmaceutically acceptable excipient. In certain embodiments, the disclosure relates to methods of treating a cancer comprising administering an effective amount of pharmaceutical composition a asparagine endopeptidase inhibitor disclosed herein to a subject in need thereof.
本公开涉及用于治疗癌症的天冬酰胺内肽酶抑制剂及其相关组合物。在某些实施方案中,天冬酰胺内肽酶抑制剂是取代的3,7-二氢嘌呤-2,6-二酮衍生物,用于治疗或预防转移、肿瘤生长和/或癌症。在某些实施方案中,本公开涉及包含天冬酰胺内肽酶抑制剂和药学上可接受的赋形剂的药物组合物。在某些实施方案中,本公开涉及治疗癌症的方法,包括向有需要的受试者施用有效量的本文公开的天冬酰胺内肽酶抑制剂药物组合物。